Supplement 

Diabetic Retinopathy and Macular Oedema – UK Pathways and Management

Volume 34 | Supplement 1

This document provides a review on DR pathophysiology, clinical features, including grading/classification of DMO. Screening and hospital interphasing are discussed. Guidance is provided on DR management, and optimal/suboptimal response to DMO therapies. Reducing service pressures with virtual clinics are also summarized.

Sponsorship: This study and publication costs were provided through an unrestricted education grant from Allergan International. Editorial assistance was provided to the authors by Dr Mark Hillen, BSc, PhD, through an unrestricted grant funding by Allergan International plc, Dublin, Ireland. Neither honoraria nor payments were made for authorship and authors retained full control over the manuscript. Allergan had the opportunity to review the final version of the manuscript to address any factual inaccuracies or request the redaction of information deemed to be proprietary or confidential and ensure that study support was disclosed.

Content